Madrigal Pharmaceuticals Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | +64.2% | -46.1% | -23.1% | +123.9% | -20.7% | -49.7% | +10.5% | -21.7% | +143.4% | -7.6% | +5.7% | -32.3% | -39.6% | +366.7% | +152.4% | -8.9% | -35.1% | -4.8% | +32.6% | +76.7% | +62.7% | +20.9% | |
| – | – | – | +63.5% | -50.0% | -24.3% | +145.7% | -22.0% | -51.1% | +15.6% | -21.8% | +151.7% | -9.0% | +7.7% | -99.6% | +11,233.7% | +366.0% | +152.7% | -9.3% | -35.2% | -4.7% | +33.0% | +76.4% | +62.1% | +20.6% | |
| – | – | – | +18.5% | -44.3% | +41.5% | +243.1% | -55.0% | -15.2% | -29.1% | -3.9% | +171.0% | -40.5% | -5.1% | -24.0% | +15.8% | +267.0% | -61.4% | -18.6% | +15.6% | -32.8% | +814.1% | -69.9% | +0.1% | +98.7% | |
| – | – | – | +63.9% | -50.3% | -24.5% | +146.8% | -36.4% | -40.0% | +15.4% | -22.1% | +153.2% | -9.1% | +6.8% | -31.9% | -39.2% | +372.9% | +152.6% | -9.2% | -35.3% | -4.9% | +32.7% | +76.7% | +46.1% | +6.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -84.1% | – | – | – | – | – | – | – | – | – | +149.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +119.7% | |
| – | – | – | – | – | – | – | – | – | – | – | -16.6% | -100.0% | – | – | -99.3% | +10,117.2% | -24.6% | +421.6% | -11.6% | +57.4% | -63.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +56.1% | |
| – | – | – | +302.3% | +33.2% | +201.8% | +72.9% | +59.6% | -84.6% | +27.5% | -9.9% | +1.5% | +65.0% | -22.9% | -49.9% | -73.0% | +109.5% | -16.0% | +201.9% | +84.5% | +64.2% | +113.9% | +42.4% | +22.4% | +128.2% | |
| – | – | – | +268.3% | +12.4% | -20.2% | +79.9% | +60.4% | -50.6% | +1.6% | -9.5% | +55.0% | +37.1% | -4.1% | +59.5% | -90.3% | +109.5% | -16.0% | +197.6% | +85.3% | +65.0% | +50.8% | +2.3% | +42.8% | +83.3% | |
| – | – | – | – | +256.6% | +21.7% | +3.3% | +80.4% | -70.9% | -84.1% | +2,012.4% | +87.2% | +19.9% | -2.9% | +430.4% | – | – | – | – | +1.0% | +28.9% | +46.8% | -12.5% | +86.5% | +3.6% | |
| – | – | – | +1,280.4% | +16.5% | -21.7% | -5.5% | +33.9% | +18.8% | -51.4% | +80.1% | +63.3% | +16.4% | -52.4% | -96.7% | +644.9% | +153.1% | +28.9% | -52.6% | -13.7% | +2,002.3% | +11.5% | +17.7% | +55.5% | +12.1% | |
| – | – | – | – | – | – | – | – | – | – | – | -64.0% | -100.0% | – | -100.0% | – | – | – | – | – | – | – | +134.3% | +1.8% | +189.1% | |
| – | – | – | +53.4% | -55.5% | -103.3% | – | -336.1% | – | -5.7% | -37.1% | +408.1% | -34.6% | +32.7% | -22.6% | -27.8% | +400.6% | +161.7% | -12.7% | -42.4% | -18.3% | +0.7% | +105.3% | +86.1% | -20.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +310.9% | +81.5% | -14.4% | +19.0% | +0.1% | +45.8% | +3.9% | +1.1% | +18.3% | +16.9% | +25.9% | +19.5% | +38.8% | -93.9% | +2,943.6% | +135.3% | +20.8% | +4.0% | +0.3% | +7.0% | +3.6% | +9.0% | +13.8% | +5.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.